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of bone marrow cells to treat liver ﬁbrosis, however, little is
known about their antiﬁbrotic efﬁcacy or the identity of their
effector cell(s). Sphingosine-1-phosphate (S1P) mediates
egress of immune cells from the lymphoid organs into the
lymphatic vessels; we investigated its role in the response of
hematopoietic stem cells (HSCs) to liver ﬁbrosis in mice.
METHODS: Puriﬁed (c-kitþ/sca1þ/lin-) HSCs were infused
repeatedly into mice undergoing ﬁbrotic liver injury. Chronic
liver injury was induced in BoyJ mice by injection of carbon
tetrachloride (CCl4) or placement on a methionine-choline–
deﬁcient diet. Some mice were irradiated and given
transplants of bone marrow cells from C57BL6 mice, with
or without the S1P antagonist FTY720; we then studied HSC
mobilization and localization. Migration of HSC lines was
quantiﬁed in Transwell assays. Levels of S1P in liver, bone
marrow, and lymph ﬂuid were measured using an enzyme-
linked immunosorbent assay. Liver tissues were collected
and analyzed by immunohistochemical quantitative
polymerase chain reaction and sphingosine kinase activity
assays. We performed quantitative polymerase chain reaction
analyses of the expression of sphingosine kinase 1 and 2,
sphingosine-1-phosphate lyase 1, and sphingosine-
1-phosphate phosphatase 1 in normal human liver and
cirrhotic liver from patients with alcohol-related liver disease
(n ¼ 6). RESULTS: Infusions of HSCs into mice with liver
injury reduced liver scarring based on picrosirius red staining
(49.7% reduction in mice given HSCs vs control mice;
P < .001), and hepatic hydroxyproline content (328 mg/g in
mice given HSCs vs 428 mg/g in control mice; P < .01). HSC
infusion also reduced hepatic expression of a-smooth muscle
actin (0.19 ± 0.007-fold compared with controls; P < .0001)
and collagen type I a 1 chain (0.29 ± 0.17-fold compared with
controls; P < .0001). These antiﬁbrotic effects were
maintained with infusion of lymphoid progenitors that lack
myeloid potential and were associated with increased
numbers of recipient neutrophils and macrophages in liver. In
studies of HSC cell lines, we found HSCs to recruit monocytes,
and this process to require C-C motif chemokine receptor 2. In
ﬁbrotic liver tissue from mice and patients, hepatic S1P levels
increased owing to increased hepatic sphingosine kinase-1
expression, which contributed to a reduced liver:lymph S1P
gradient and limited HSC egress from the liver. Mice given the
S1P antagonist (FTY720) with HSCs had increased hepaticretention of HSCs (1697 ± 247 cells in mice given FTY720 vs
982 ± 110 cells in controls; P < .05), and further reductions
in ﬁbrosis. CONCLUSIONS: In studies of mice with chronic
liver injury, we showed the antiﬁbrotic effects of repeated
infusions of puriﬁed HSCs. We found that HSCs promote
recruitment of endogenous macrophages and neutrophils.
Strategies to reduce SIP signaling and increase retention of
HSCs in the liver could increase their antiﬁbrotic activities
and be developed for treatment of patients with liver ﬁbrosis.Keywords: Mouse Model; CCR2; Sphingolipid; Immune Cell
Localization.
he incidence of chronic liver disease is increasing
1Tworldwide and is characterized by the progres-
sion of liver injury from hepatic ﬁbrosis to cirrhosis,
resulting in death from liver failure, complications of
portal hypertension, or hepatocellular carcinoma.2 At
present, liver transplantation remains the only curative
treatment for end-stage liver disease but is limited by the
availability of donor organs and the risks of lifelong
immunosuppression.3–5 The development and resolution
of hepatic ﬁbrosis is recognized as a bidirectional process,
with resolution of ﬁbrosis mediated through degradation
of hepatic collagen6 and apoptosis of activated hepatic
myoﬁbroblasts.7
EDITOR’S NOTES
BACKGROUND AND CONTEXT
There are no proven anti-ﬁbrotic therapies in liver disease.
Haematopoietic stem cells (HSC) have been suggested as
being potentially efﬁcacious in this setting, although this
has not been well studied.
NEW FINDINGS
Repeated injections of puriﬁed HSC markedly reduced
liver ﬁbrosis and improved liver function. This effect was
increased by the co-administration of FTY720, a partial
S1P receptor agonist, which enhanced their retention
inside the liver.
LIMITATIONS
This study, while suggesting that HSC mediate their anti-
ﬁbrotic effect through recruitment of endogenous
monocytes and neutrophils, does not conclusively
identify the mechanisms mediating their anti-ﬁbrotic
effect.
IMPACT
There is a need for new therapies for patients with chronic
liver disease, and this study demonstrates the therapeutic
potential of treatment with HSC.
234 King et al Gastroenterology Vol. 153, No. 1
BASIC
AND
TRANSLATIONAL
LIVERInitial observations that bone marrow cells may
contribute to hepatic repair and regeneration8–10 were fol-
lowed by studies in animal models of chronic liver injury
showing variable therapeutic effects.11–14 Despite these
mixed outcomes, multiple clinical studies of bone marrow
(BM)-derived stem cell therapy already have been
performed.15–17 The design of these studies has not
permitted any meaningful conclusions and larger random-
ized controlled trials are underway.
The heterogeneous nature of the bone marrow cell
populations studied to date has limited our understanding
of their beneﬁcial effects and prevented elucidation of
potential mechanisms. Hematopoietic stem cells (HSCs)
reside with the bone marrow niche, provide continual
renewal and replacement of all blood cell lineages,18 and
can be isolated routinely using cell surface markers.19 The
continual homeostatic recirculation of bone marrow stem
cells recently was described and the bioactive sphingolipid
sphingosine 1-phosphate (S1P) was identiﬁed as a key
regulator of this process.20 An S1P concentration gradient
between body compartments is established by varying
tissue distribution of sphingosine kinase (SPHK1/2) and
sphingosine-1-phosphate lyase (SGPL)/sphingosine-
1-phosphate phosphatase (SGPP),21,22 and this gradient
regulates the egress of HSCs from peripheral tissue into
draining lymphatics. Binding of FTY720, a functional
antagonist, to S1P receptors results in internalization and
ubiquitin-dependent degradation without downstream
signaling, thus rendering cells unresponsive to S1P.23 This
blocks egress of HSCs, resulting in an accumulation of HSCs
within peripheral tissues.20
We studied the effect of chronic liver injury on HSC
mobilization and recruitment to the liver and showed
reduced hepatic ﬁbrosis after repeated therapeuticadministration of a puriﬁed population of HSCs. Further-
more, we observed changes in S1P expression in chronic
liver injury and showed prolonged hepatic retention of HSCs
after administration of FTY720, which resulted in a further
signiﬁcant reduction in liver ﬁbrosis when administered in
conjunction with c-kitþ, sca-1þ and lineageneg (KSL) cell
injections.Materials and Methods
Murine Models of Liver Injury
Mice were housed in a temperature-controlled sterile animal
facility with 12-hour light/dark cycles and free access to food
and water. All experiments were conducted in accordance with
the University of Birmingham ethics policy and the UK Animals
(Scientiﬁc Procedures) Act 1986 (project license PPL 40/3201).
C57/BL6 mice were obtained from Charles River Laboratories
(London, UK) and BoyJ mice were obtained from a colony
maintained at the Biomedical Services Unit of the University of
Birmingham. To induce chronic liver injury, carbon tetrachloride
(CCl4) (1 mg/kg diluted 1:4 in mineral oil; Sigma, London, UK)
was injected twice weekly for 9 weeks, with control mice
receiving mineral oil vehicle only. In separate experiments mice
were fed either standard chow or a methionine-choline–deﬁcient
diet (MP Biomedical, London, UK) for 6 weeks.
Experimental Protocols
Six- to 8-week-old female BoyJ mice received twice-weekly
intraperitoneal injection of CCl4 (1 mg/kg in mineral oil) for
6 weeks, and then were allocated randomly to receive either
puriﬁed cells isolated from 6- to 8-week-old male C57BL6 mice
as described, or no treatment. Cell injections were administered
on the ﬁrst day of weeks 7, 8, and 9 of liver injury, and mice
were killed 1 week after the ﬁnal cell injection and 72 hours
after the ﬁnal CCl4 injection. In some experiments FTY720
(Cayman Chemicals, Cambridge, UK; 1 mg/kg in phosphate-
buffered saline þ 0.1% dimethyl sulfoxide) or vehicle control
was administered by intraperitoneal injection 3 times per week
from week 6 until death.
Bone Marrow Transplantation
Six-week-old C57/BL6 mice received lethal irradiation
(9 Gy in 2 divided doses) followed by transplantation via tail
vein injection of 1  108 whole bone marrow cells isolated
from 6-week-old BoyJ mice. After 4 weeks, mice were
allocated randomly to receive either twice-weekly injection of
CCl4 (1 mg/kg) or mineral oil vehicle, for 8 weeks followed by
death.
Immunohistochemistry
Picrosirius red (PSR) staining was performed using 0.1%
Direct Red 80 (Sigma) in saturated picric acid according to
standard protocols. Quantiﬁcation of PSR and a-smooth muscle
actin (a-SMA) staining was performed by threshold analysis of
10 nonoverlapping randomly selected ﬁelds of view per slide at
a magniﬁcation of 20 using ImageJ software (National
Institutes of Health, Bethesda, MD), and was expressed as the
percentage of positive staining of the total area. F4/80 and
Ly6G staining was quantiﬁed by counting individual positive
Figure 1. Liver injury increases mobilization and recruitment of HSCs to the liver. (A) KSL cells were quantiﬁed by ﬂow
cytometry and representative plots are shown. (B) Numbers of KSL cells were quantiﬁed in the peripheral blood, livers, and BM
of CCl4-, methionine-choline–deﬁcient (MCD), and mineral oil–treated mice. Data from individual mice are shown with means
indicated by the horizontal line (n ¼ 6 per group). (C) Colony-forming potential of cells isolated from liver, blood, and bone
marrow were quantiﬁed in myeloid colony-forming unit (CFU) assays. Data from individual mice are shown with means
indicated by the horizontal line (n ¼ 6 per group). (D) BoyJ (CD45.1) mice were irradiated lethally (9 Gy in 2 divided doses) and
received unfractionated BM from C57Bl/6 (CD45.2) mice followed by administration of CCl4 or mineral oil for 8 weeks. Higher
numbers of bone marrow–derived CD45.2þ KSL were found in the blood and livers of mice after CCl4 liver injury (n ¼ 6 per
group). *P < .05, **P < .01, and ***P < .001.
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slide at magniﬁcations of 20 and 100 and expressed as cells
per ﬁeld of view.S1P and SphK Quantiﬁcation
SphK activity was determined using the Sphingosine Kinase
Activity Assay (K-3500; Echelon, Le-Perray-en-Yvelines,
France) according to the manufacturer’s instructions. A stan-
dard curve was created and results were normalized to the
protein content of the sample and time (pmol S1P/mg protein/
min). S1P concentrations were measured using the sphingo-
sine-1-phosphate enzyme-linked immunosorbent assay kit
(K-1900; Echelon) according to the manufacturer’s
instructions, S1P concentrations in serum and lymph ﬂuid were
expressed as molar quantities and in liver and bone marrow
were normalized to the protein content of the sample (pmol
S1P/mg protein).IV
ERChemotaxis Assay
A total of 600 mL Stem Pro 34 serum-free media alone or
containing the relevant concentration of S1P (Cayman Chem-
icals) was placed in individual wells of a 12-well plate (Corning,
London, UK) and 6.5-mm Transwell inserts (5-mm pore diam-
eter) placed in each well. A total of 100 mL of cell suspension
(1  106 cells/mL) was added to the insert and incubated for
3 hours. Cell migration was assessed by quantiﬁcation of the
number of cells in each lower well using ﬂow cytometry as
described; migration was expressed as a percentage of the
input cells in the lower well. S1P and FTY702-P were prepared
by dissolving in 95% dimethyl sulfoxide/5% 1 N HCl (Sigma)
and diluted for use in phosphate-buffered saline þ 3% fatty
acid free bovine serum albumin (Sigma). W146 (Sigma) was
dissolved in methanol containing 0.05% acetic acid and diluted
for use in cell culture media.BA
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Studies of HSC trafﬁcking have been limited by difﬁculties
in isolating a sufﬁcient number of cells, in some experiments
in this study we used an immortalized HSC line (hematopoi-
etic progenitor cell line 7 [HPC-7]), which expresses common
murine HSC markers and transcription factors,24 which have
been used in previous studies of HSC recruitment.25 HPC-7
cells were cultured in StemPro Serum Free Media 34
(Invitrogen, London, UK) supplemented with penicillin,=
Figure 2. Repeated injection of HSC KSL reduced hepatic ﬁ
induced in 8-week-old C57/Bl6 mice by 8 weeks of twice-week
groups of 8 and 1 group received injections of 5  104 KS
photomicrograph images of PSR of livers show a reduction in c
bridging ﬁbrosis, compared with untreated control mice (ma
obtained from each section and staining was quantiﬁed as a
ImageJ software. (B) Quantitative analysis of picrosirius re
hydroxyproline content veriﬁed the reduction in hepatic ﬁbro
stellate cells, as indicated by (D) representative photomicro
injections, which was conﬁrmed by morphometric analysis of h
a-SMA and col1a1. (F) Serum albumin levels were higher in mic
indicated by Pan-CK were increased after KSL cell administ
experiments. *P < .05, **P < .01, and ***P < .001 vs control.streptomycin, glutamine, and 100 ng/mL recombinant murine
Stem Cell Factor (Invitrogen). For colony-forming unit assays
cells were added to MethoCult GF media (Stem Cell Tech-
nologies, Cambridge, UK) and incubated for 10 days, and the
total number of myeloid colonies per assay were determined
by counting under low-power magniﬁcation.Statistics
Statistical analyses were performed using GraphPad (La
Jolla, CA) Prism version 5.0. Differences between groups
were analyzed using either the 2-tailed unpaired Student t
test or multiple group comparisons with 1-way analysis of
variance with Bonferroni post-test correction unless other-
wise stated. A result was considered signiﬁcant when the P
value was less than .05.
Results
Bone Marrow–Derived HSCs Are Mobilized
and Recruited to the Liver During
Chronic Liver Injury
The effect of liver injury on the mobilization and
recruitment of BM-derived HSCs was investigated in the
model of CCl4-induced liver injury. Higher numbers of HSCs
(KSL), were isolated from the peripheral blood
(0.397 ± 0.05 vs 0.065 ± 0.07 KSL cells/mL blood;
P < .001) and liver (1163 ± 173 vs 258.5 ± 22 KSL cells/
liver; P < .01) of mice with a CCl4 injury compared with
control mice (Figure 1B). There also were marked
increases in colony-forming unit potential from cells
isolated from liver and peripheral blood, but not BM, in
CCl4 injury (Figure 1C). Similar results were seen in the
setting of methionine-choline–deﬁcient diet–induced liver
injury. Liver resident populations of HSCs have been
described (Taniguchi et al 199626) and further studies to
conﬁrm the bone marrow origin of the isolated KSL cells
were performed. Bone marrow chimerism was established
(Supplementary Figure 1) and donor BM-derived HSCs
were identiﬁed as CD45.2þ KSL. Signiﬁcant increases in
CD45.2þ KSL cells were observed within the liver
(788.2 ± 59 vs 292.6 ± 45; P < .01) and peripheral blood
(0.333 ± 0.06 vs 0.077 ± 0.01; P < .01) of CCl4-injured
mice (Figure 1D), whereas BM populations remained
constant. Given the mobilization and hepatic recruitment ofbrosis in a model of CCl4 liver injury. (A) Liver injury was
ly intraperitoneal injections of CCl4. Mice were divided into 2
L cells via tail vein at weeks 6, 7, and 8. Representative
ollagen staining of livers from KSL-treated mice, with loss of
gniﬁcation, 40). Six random nonoverlapping images were
percentage of the image positive for PSR and a-SMA using
d staining and (C) biochemical measurement of hepatic
sis after KSL injections. The number of activated hepatic
graph images of a-SMA staining, was reduced after KSL
epatic a-SMA staining and by (E) hepatic gene expression of
e receiving KSL injections. (G) Hepatic oval cell numbers, as
ration. Data are from n ¼ 8 per group and 3 independent
Figure 3. Impact of administered HSCs on endogenous cell recruitment and expansion in the injured liver. There was marked
expansion in the number of (A) recipient-derived Ly6G and (B) F4/80-immunopositive cells in the livers of mice after KSL
injection as indicated in representative photomicrographs. (A) Ly6G and (B) F4/80 cells were counted manually in 6 random
nonoverlapping ﬁelds of view (100 F4/80, 20 Ly6G). (C) MMP9 and MMP13 expression in the liver was seen to increase
after KSL cell administration, in association with a (D) reduced Arg-1/iNOS expression ratio. (E) Flow cytometric analysis of the
digested livers (gating strategy is described in the Supplementary Materials and Methods section) characterized the
macrophage subsets within the liver. (F) Murine monocytes were seen to transmigrate toward CCL2 and HPC-7 HSCs in a
dose-dependent fashion. (G) Migration of murine monocytes toward HPC-7 was chemokine-dependent and inhibited by
neutralizing CCR2 antibody. Data are from n ¼ 8 per group and 3 independent experiments, expressed as means ± SD of the
number of cells per ﬁeld of view shown or medians ± interquartile range. *P < .05, **P < .01, and ***P < .001.
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administering puriﬁed HSCs was investigated.Infused KSL Cells Reduce Fibrosis in the CCl4
Model of Liver Injury
KSL HSCs were isolated from donor bone marrow and
purity of more than 96% was conﬁrmed in all experiments
(Supplementary Figure 2). Repeated injections of KSL cells
(Figure 2A) resulted in a 49.7% reduction in hepatic
ﬁbrosis determined by PSR quantiﬁcation (2.21% ± 0.12%
vs 4.38% ± 0.27% staining; P < .0001) (Figure 2B), and by
reduced hepatic hydroxyproline content (328.5 ± 30.4 vs
428.4 ± 31.9 mg/g liver; P < .05) (Figure 2C). Resolution of
ﬁbrosis is dependent on apoptosis of a-SMAþ myoﬁbro-
blasts within the liver, and a-SMA staining was 65.6%
lower after KSL cell injections (2.42 ± 0.2 vs 7.05 ± 0.33;
P < .0001) (Figure 2D) and was associated with down-
regulation of hepatic a-SMA (0.19 ± 0.007-fold vs con-
trol; P < .0001) and col1a1 (0.29 ± 0.17-fold vs control;
P < .0001) gene expression (Figure 2E). Serum albumin
level was higher in treated mice than in untreated controls
(4.06 ± 0.37 vs 3.14 ± 0.39; P < .01) (Figure 2F). There
also were increases in hepatic oval cell numbers
(Figure 2G).BA
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Enhancement of Endogenous Repair
Mechanisms
The fate of injected cells was investigated, but donor-
derived CD45.2þ cells could not be detected in
signiﬁcant numbers within the liver 7 days after injec-
tion. Quantiﬁcation of cell populations within the liver
showed a 219% increase in neutrophils (12.4 ± 2.7 vs
5.646 ± 2.51 Ly6Gþ cells per ﬁeld of view; P < .0001)
and a 177% increase in macrophages (44.2 ± 11.8 vs
24.99 ± 7.5 F4/80þ cells per ﬁeld of view; P < .0001)
after KSL injections (Figure 3A and B). The absence of
CD45.2 staining indicated that these increases were
caused by increases in endogenous cell populations
rather than differentiation of injected KSL. Although
there were increases in matrix metalloproteinase (MMP)
9- and MMP13-expressing cells (Figure 3C), and a
reduction in the Arg-1/iNos ratio (Figure 3C), in the
livers of mice receiving KSL infusions there were no
differences in macrophage subsets within the liver
(Figure 3E) or blood (Supplementary Figure 3A–C) after
KSL cell infusion. The ratio of Ly-6Chi/Ly-6Clo (M1-like
to M2-like) macrophages was not different between the
control (0.23) and KSL groups (0.12). Murine monocytes
migrated toward HPC-7 cells in a dose-dependent
fashion and at similar levels to chemokine (C-C motif)
ligand 2 (Figure 3F), a classic monocyte chemoattractant.
This migration was chemokine dependent, as shown by
blockade seen after pertussis toxin administration
(Figure 3G). Notably, the majority of this reduction was
achieved when a CCR2-blocking antibody was used
(Figure 3G).Antiﬁbrotic Effect of KSL Cells Occurs
Irrespective of Their Myeloid
Differentiation Potential
To explicitly establish whether antiﬁbrotic effects of
KSL were mediated through differentiation to macro-
phages, the effect of injecting committed myeloid or
lymphoid progenitor cells was determined (Figure 4A).
Common myeloid progenitors (CMPs) established myeloid
colonies whereas common lymphoid progenitors (CLP)
did not (Figure 4B). Repeated injections of either
progenitor population resulted in reduced hepatic ﬁbrosis
(Figure 4C and D), including a reduction in PSR staining
(CMP, 1.94% ± 0.29%; CLP, 2.27% ± 0.13%; vs control,
4.38% ± 0.27% staining; P < .01 both vs control)
(Figure 4C) and a reduction in a-SMA staining (CMP,
2.79% ± 0.25%; CLP, 3.69% ± 0.33%; vs control
7.05% ± 0.39% staining; P < .05 both vs control)
(Figure 4D). This antiﬁbrotic effect was similar to that
observed with injections of KSL and conﬁrmed that
myeloid differentiation was not required to mediate this
effect. As with KSL cells, infusions of CMP and CLP cells
also were associated with histologic evidence of increased
numbers of endogenous Ly6G neutrophils and F4/80
macrophages (Figure 4F and G) in the liver.
Hepatic Sphingosine-1-Phosphate Expression
and Activity Increases in Rodent and Clinical
Liver Injury
Because S1P, mediated by differences in concentration
gradients, regulates the homeostatic trafﬁcking of HSCs
between tissue compartments, we determined changes in
liver injury. In CCl4 injury S1P levels were 1.7-fold higher in
the liver (68.79 ± 7.42 vs 39.45 ± 7.06 pmol per mg protein;
P < .05) and 1.5-fold higher in the serum (1.71 ± 0.13 vs
1.15 ± 0.18 mmol/L; P < .01) with no signiﬁcant change in
BM or lymph concentrations (Figure 5A). To determine the
factors inﬂuencing S1P levels we studied its cognate
metabolizing enzymes. SphK1 phosphorylates sphingosine
to produce S1P, and hepatic gene expression of SphK1 was
up-regulated during murine CCl4 liver injury
(5.57 ± 0.65-fold vs control; P < .0001), whereas expression
of sphingosine kinase 2, SGPL, and SGPP remained
unchanged (Figure 5B). Similar ﬁndings were observed in
human chronic liver disease (Figure 5C). SphK1
up-regulation was not seen outside the murine liver
(Supplementary Figure 4) and also was observed in mice
fed the methionine-choline–deﬁcient diet, an alternative
model of chronic liver injury (Figure 5B). Analysis of
isolated murine cell types showed signiﬁcant up-regulation
of SphK1 gene expression in liver sinusoidal endothelial
cells during liver injury (5.26 ± 1.26-fold vs control;
P < .001) without signiﬁcant alteration in hepatocyte or
peripheral blood mononuclear cell gene expression
(Figure 5D). SphK1 expression was 12-fold higher in human
subjects with chronic liver disease than in normal controls
(12.55 ± 6.1-fold vs control; P < .01) (Figure 5C), and this
observation held true for different etiologies of liver disease
(Supplementary Figure 5). SphK1 was the most abundant
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eral blood mononuclear cells, whereas hepatocytes
predominantly expressed SGPL and SGPP (Figure 5E).
Increased SphK1 was detected by Western blot (Figure 5F)
in both murine and human chronic liver injury, and SphK1
enzymatic activity was 2.7-fold higher (5.76 ± 0.95 vs
2.07 ± 0.25 nmol/min/mg protein; P < .01) (Figure 5G) in
liver tissue from mice with CCl4 injury. SphK1 enzymatic
activity also was increased in chronically diseased human
liver tissue (Figure 5H).BA
SI
C
AN
D
TR
AN
SL
AT
IO
NA
L
LI
VE
RBlocking Migration to S1P with FTY720
Speciﬁcally Increases Retention of KSL Cells in
the Injured Liver
S1P1 was the most highly expressed S1P receptor on
KSL, which was found predominantly intracellularly
(Supplementary Figure 6A and B). In vitro migration to
S1P was dose-dependent and peaked at 1 mmol/L
(Supplementary Figure 6C).The HPC-7 cell line had similar
c-kit/sca-1 expression (with absence of lineage markers),
comparable S1P/chemokine receptor expression
(Supplementary Figure 7), and migrated to S1P in vitro
(Supplementary Figure 8E). Treatment of KSL with FTY720
markedly impaired S1P-dependent cell migration
(Supplementary Figure 6D), as did treatment with the
S1P1-speciﬁc antagonist W146. After administration of
FTY720 to mice with CCl4 injury, higher numbers of KSL
were isolated from liver (1697 ± 247 vs 982 ± 110 KSL
cells/liver; P < .05), whereas the number of circulating
KSL in peripheral blood was not altered (0.36 ± 0.1 vs
0.43 ± 0.14 KSL cells/mL) (Supplementary Figure 6E).
1,10-dioctadecyl-3,3,30,30-tetramethylindotricarbocyanine
iodide (DiR) labeling of KSL did not affect their viability or
proliferation and ﬂuorescence intensity of labeled cells was
maintained at 7 days without transfer of dye to unlabeled
cells (Supplementary Figure 9). DiR-labeled HPC-7 cells
were used to study the tissue distribution of injected HSCs,
which showed rapid clearance from the lungs over the ﬁrst
24–48 hours and ongoing accumulation within the liver
over 48 hours followed by gradual clearance (Figure 6A–C).
Only low levels of uptake were found in the spleen and
kidneys. Administration of FTY720 did not alter initial
localization of injected cells in either the liver or lungs,
however, the numbers of HPC-7 remaining within the liver=
Figure 4. Committed HSC subsets without myeloid propertie
plots of common myeloid progenitors and common lymphoid
(CMP, interleukin [IL]7Ra- c-kitþ sca1þ lineage-; CLP, interleu
able to form myeloid colonies in vitro, whereas CLP lacked
colonies per 500 plated cells shown (±SD) from 3 separate iso
6, 7, and 8 of CCl4 injury resulted in a similar reduction in hep
quantitative analysis of picrosirius red staining, biochemical m
gene expression for col1a1. (D) Similarly, CMP and CLP injec
cells to a level seen with KSL injections, as indicated by morp
gene expression of a-SMA. (E) Serum albumin levels also w
increased numbers of (F) endogenous Ly6G neutrophils and
infusions. Data are from n ¼ 8 per group and 3 independentwere 50% higher than control 4 days after injection and
were 86% at 7 days (Figure 6A–C). Based on these ﬁndings,
tissue localization of KSL cells was studied at a single time
point, 4 days after injection. Greater numbers of injected
KSL cells were found within the liver in mice treated with
FTY720 compared with untreated controls (13,514 ± 1506
vs 7687 ± 1556 DiR-labeled KSL cells/liver; P < .05)
(Figure 6D). Intravital microscopy studies showed that
treatment of KSL cells with FTY720 or W146 did not
increase their recruitment to the injured liver (control,
10.3 ± 0.6; FTY720, 9.6 ± 2.4; W146, 9.0 ± 1.15 cells/ﬁeld
of view) 60 minutes after injection (Figure 6E and F).Increased Retention of KSL Cells in the Injured
Liver With FTY720 Enhances Their Antiﬁbrotic
Effect
Administration of FTY720 alone did not alter hepatic
ﬁbrosis or a-SMA activation (Supplementary Figure 10).
Administration of FTY720 in conjunction with repeated KSL
cell injections resulted in a further 16% reduction in PSR
staining (1.86% ± 0.10% vs 2.21% ± 0.11% staining;
P < .05) (Figure 7A and B) and a 12% reduction in hepatic
hydroxyproline content (289.2 ± 90.9 vs 328.9 ± 83.6;
P ¼ .05) (Figure 7C) compared with KSL cell injection alone.
a-SMA staining was 21% lower (1.82 ± 0.19 vs 2.31 ± 0.22;
P < .05) (Figure 7D) in the FTY þ KSL group and hepatic
gene expression of a-SMA and Col1a1 remained suppressed
in both groups (Figure 7E).Conclusions
Despite the considerable interest in bone marrow cell
therapy for liver disease there is still signiﬁcant uncer-
tainty regarding their efﬁcacy. Moreover, there is also a
lack of clarity as to which population of bone marrow cells
is likely to be the most effective. In this article we show
that repeated injections of a puriﬁed population of murine
hematopoietic stem cells result in a marked resolution of
hepatic ﬁbrosis, in association with an increase in hepatic
populations of endogenous macrophages and neutrophils.
In addition, we show that abrogation of the migration of
hematopoietic stem cells down an S1P gradient results in
their greater hepatic retention and a further reduction in
liver ﬁbrosis, thus establishing a new therapeutics also are able to reduce liver ﬁbrosis. (A) Representative
progenitors were isolated using surface antigen expression
kin [IL]7Raþ c-kitlo sca1lo lineage-). (B) KSL and CMP were
this ability. Data are expressed as the mean number of
lations. (C) Tail vein injections of CMP or CLP cells at weeks
atic ﬁbrosis to that seen with KSL injections as assessed by
easurement of hepatic hydroxyproline content, and hepatic
tions also reduced the number of activated hepatic stellate
hometric analysis of hepatic a-SMA staining and by hepatic
ere increased after CMP and CLP injections. There were
(G) F4/80 macrophages in the liver after CMP and CLP
experiments. *P < .05 vs control.
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setting.
It previously has been proposed that injected bone
marrow cells differentiate into antiﬁbrotic cells of a
monocyte/macrophage lineage.11 However, we have
shown that myeloid differentiation is not required for cells
to exert their antiﬁbrotic effect in our study because
injection of lymphoid progenitor cells induced a similar
amount of ﬁbrosis resolution as injections of either
myeloid progenitors or HSCs. Neutrophils and
macrophages, with expression of MMP9 and MMP13, are
critical to the resolution of ﬁbrosis27,28 and signiﬁcant
increases in these cell populations were observed in the
livers of mice receiving cell injections. The experimental
design of this study, using a CD45 mismatch, conﬁrmed
that these cells were recipient-derived, representing
activation of endogenous repair pathways rather than a
direct antiﬁbrotic action of the injected cells. These
ﬁndings clarify that HSCs exert a paracrine effect within
the injured liver, stimulating repair through recruitment of
other cell populations, and indeed HSCs have been shown
to be potent secretory cells, mediating effector properties
through cytokine stimulation of immune cell pop-
ulations.29 Further study of the chemokines and cytokines
(eg, CCL2, interleukin 10, tumor necrosis factor-like weak
inducer of apoptosis [TWEAK]) secreted by HSCs may
further deﬁne the mechanisms involved. Notably, our data
indicate that murine monocytes, which may mediate the
antiﬁbrotic effect of HSCs, are recruited to CCL2 and also
to murine HPC-7 cells in a CCR2-dependent manner, sug-
gesting that a potential mechanism by which monocytes
are recruited/positioned within the injured liver relates to
hematopoietic stem cell–expressed/secreted chemokine
ligands. There were no differences in the proportion of=
Figure 5. Regulation of S1P levels in murine and human chro
CCl4 or mineral oil (MO) by intraperitoneal injection twice we
sera of mice after 8 weeks of CCl4 liver injury compared wi
lymph (n ¼ 5 per group). (B) Hepatic expression, by quantit
but there were no changes in gene expression for other
regulation (n ¼ 6 per group). A similar pattern of gene ex
deﬁcient (MCD) diet, an alternative model of chronic liver
SphK1, SphK2, SGPL1, and SGPP1 were quantiﬁed in norm
with alcohol-related liver disease (n ¼ 6 per group). (D) An
livers showed up-regulation of SphK1 gene expression
hepatocytes or peripheral blood mononuclear cells when co
experiments). Gene expression also was studied in cons
associated peripheral blood mononuclear cells (n ¼ 6 per
assessed by intravital microscopy. (F) There was an increase
Western blot (representative of 3 independent experiment
triphosphate depletion assay to measure the enzymatic acti
panel). (G) The rate of phosphorylation of sphingosine to S1
rate of depletion of adenosine triphosphate and expresse
protein (n ¼ 5 per group). (F) Samples of human liver tis
SphK1 and glyceraldehyde-3-phosphate dehydrogenase (G
experiments) showed an increase in all cirrhotic liver samp
Sphingosine to S1P was higher in human chronic liver inju
expressed as nmol of S1P produced per minute per mg of
control. AIH, autoimmune hepatitis; ALD, alcoholic liver d
peripheral blood mononuclear cell.macrophage subsets within the liver, or as a ratio of
Ly-6Chi/Ly-6Clo (M1-like to M2-like) macrophages, after
KSL cell infusion. Similarly, no differences were seen in
peripheral blood analysis. As recognized by the literature,
surface marker expression of macrophages is likely to be
more complex and dynamic and thus even extensive
panels do not completely characterize the full phenotype
of macrophages in vivo.30 The integral role of macro-
phages in mediating both the generation and resolution of
ﬁbrosis has been shown by other groups, including our
previous work.31,32
It is assumed that homing of HSCs to the injured liver is
required for them to exert their antiﬁbrotic actions,
although this has not been proven. Increased recruitment
of hematopoietic stem cells to the liver has been reported
in response to stress-induced signals, such as increased
expression of stromal-derived factor-1, MMP9, and hepa-
tocyte growth factor, which recruit human CD34þ
progenitors.33 We previously reported that the adhesion of
human hematopoietic (CD34þ) stem cells to human liver
compartments is integrin- and CD44-dependent and
modulated by CXC chemokine receptor 3 and CXC che-
mokine receptor 4.34 Our BM transplantation studies
conﬁrmed that liver injury with CCl4 increases the number
of BM-derived HSCs in the liver, but without any change in
the number of HSCs in other organs. There have been a
variety of different approaches taken to the administration
of stem cell therapy in both human beings and animal
models, the peripheral venous route represents the safest
and most feasible mode of delivery and we have shown
this to be effective because cells injected into a peripheral
vein exert a beneﬁcial therapeutic effect. Analysis of the
distribution of injected HSCs showed their accumulation
within the lungs immediately after injection followed by anic liver injury. (A) Eight-week-old C57/BL6 mice received
ekly for 8 weeks. S1P levels were higher in the livers and
th MO controls, but were unchanged in bone marrow and
ative polymerase chain reaction, of SphK1 was increased,
enzymes (SphK2, SGPL1, and SGPP1) involved in S1P
pression was observed in mice fed a methionine-choline
injury (n ¼ 6 per group). (C) Hepatic gene expression of
al human liver and also human cirrhotic liver from patients
alysis of cell populations from chronically injured murine
in hepatic sinusoidal endothelial cells (LSEC), but not
mpared with MO controls (n ¼ 3 per group, 3 independent
tituent cells from explanted human cirrhotic livers and
group). (E) Represents adherent cells per ﬁeld of view as
in SphK1 protein expression in the CCl4-treated mice by
s). Samples of liver tissue were used in an adenosine
vity of SphK in injured and normal liver tissue (bottom left
P was higher in CCl4-injured mice, as determined from the
d as nmol of S1P produced per minute per mg of liver
sue were lysed for protein extraction and expression of
APDH) by Western blot (representative of 3 independent
les (top right panel). (H) The rate of phosphorylation of
ry, as determined from the rate of depletion of ATP and
liver protein (n ¼ 5 per group). *P < .05, ***P < .001 vs
isease; NAFLD, nonalcoholic fatty liver disease; PBMC,
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Rrapid clearance, whereas recruitment to the liver
increased over the ﬁrst 48 hours with a more gradual
reduction in cell numbers subsequently. Seven days after
injection the number of injected HSCs remaining within
the liver was very small and explains the absence of
detectable numbers of cells on tissue section analysis. The
whole-organ analysis in this study provided an accurate
assessment of cell numbers because previous studies have
used tissue section analysis, which may not quantify small
numbers of cells accurately or provide appropriate com-
parisons between organs, for example, overestimating the
number of injected cells within the lungs.
S1P has been recognized to mediate recirculation of
HSCs down S1P gradients from tissue back into lymph and
the circulation,20 and we show that S1P levels and activity
are increased in the injured liver, thus partially reversing
the normal S1P liver tissue:lymph gradient. Our data
suggest that the increase in hepatic S1P levels is caused by
up-regulation of SphK1 in liver sinusoidal endothelial cells
with less signiﬁcant changes in other enzymes involved in
S1P processing. To establish whether S1P was acting to
increase recruitment of bone marrow–derived cells to the
liver, we performed intravital microscopy (Figure 6E and F)
with blockade of the S1P axis using either a function-
blocking antibody to S1P1 receptor or FTY720, neither of
which altered the number of exogenously administered
bone marrow–derived cells seen within the liver over a
60-minute period. We therefore hypothesize that the
increased hepatic S1P levels act primarily to retain HSCs
within the liver by preventing their egress down the existing
S1P liver–lymph gradient rather than priming the liver to
recruit bone marrow–derived cells, which is in keeping with
the observations of others in normal physiological
conditions.20,35
To exploit this modulation of the S1P pathway we used
pharmacologic manipulation with the partial S1P1-receptor
agonist, FTY720. FTY720 impaired the migration of HSCs
in vitro and when administered to mice with liver injury=
Figure 6. FTY720 treatment increased the number of injec
administered via tail vein to CCl4-injured mice that also we
starting 1 day before cell injection and continuing for 7
ﬂuorescence intensity images of livers from mice injected w
time points after cell injection. (B) The number of DiR-la
quantiﬁed using ﬂuorescence intensity by (B) in vivo ima
digested organs up to 7 days after injection. Greater numb
2, 4, and 7 after injection in mice treated with FTY720 (blu
Greater numbers of injected DiR-labeled KSL cells were pr
group) using both ﬂuorescence intensity by IVIS (London, U
per group, 3 independent experiments). (E) To establish if S
as retention), CFSE-labeled HPC-7 were pretreated with FT
CCl4 liver injury. Recruitment of HSCs to the liver was asses
HPC-7 with FTY720 or W146 did not alter recruitment to inj
analysis of variance with the Bonferroni multiple compari
(F) After completion of intravital microscopy experimen
microscopy (ﬂuorescein isothiocyanate ﬁlter). The number
6 random nonoverlapping ﬁelds of view (magniﬁcation, 20
within the liver was seen between cells treated with FTY720
fov, ﬁeld of view.resulted in accumulation of HSCs within the liver. Although
FTY720 did not affect trafﬁcking of HSCs within the ﬁrst 48
hours after injection, increased numbers of injected HSCs
were present in mouse livers at later time points compared
with placebo controls. This supports our observations that
HSC recruitment to the injured liver is not mediated through
S1P receptors and that the increased number of HSCs in the
liver is a result of increased retention of HSCs within the
liver, rendered unresponsive to the S1P gradient by FTY720.
The use of isolated KSL cells in these tracking studies was
limited by the difﬁculties isolating the large number of cells
required, and thus the ﬁndings from experiments using the
HPC-7 cell line were used to design experiments with
isolated KSL cells at a single time point. This study, with KSL
cells, also conﬁrmed that mice receiving FTY720 had a
greater number of cells within the liver 4 days after
infusion.
Although administration of FTY theoretically could
reduce homing to any organ, our tracking data (Figure 6B
and C) indicated no change in the number of KSL cells found
in the lungs. We therefore believe that the reason FTY720
increases the number of KSL cells in the liver, without an
effect on other organs, is the result of a combination of a
reduced liver–lymphatic S1P gradient (caused by the in-
duction of liver injury, which increases hepatic S1P levels)
and a reduced tendency to migrate down an S1P axis owing
to the pharmacologic action of FTY720. Notably, FTY720 has
a range of systemic actions that in their own right may be
antiﬁbrotic, such as inhibiting cytosolic phospholipase A2
and antagonizing cannabinoid receptor 1,36 although in this
study it had no antiﬁbrotic effect when used in isolation.
The antiﬁbrotic effect of injected HSCs was augmented by
approximately 20% with the addition of FTY720, and
although the clinical signiﬁcance merits further study, any
optimization of the effect of this very rare population of cells
should be considered advantageous. The optimal number of
cells required to achieve an antiﬁbrotic effect remains un-
certain; in our studies we chose to administer lowerted HSCs within the liver. DiR-labeled HPC-7 cells were
re treated with either FTY720 (1 mg/kg) or vehicle control
days. (A) Representative combined photographic and
ith HPC-7 cells treated with either FTY720 or vehicle at
beled HPC-7 cells within the liver and lungs then were
gine system (IVIS) and (C) ﬂow cytometric analysis of
ers of DiR-labeled cells were detected in the liver at days
e line; n ¼ 3 per group, 3 independent experiments). (D)
esent in the livers of mice treated with FTY720 (n ¼ 3 per
K) and by ﬂow cytometric analysis of digested liver (n ¼ 3
1P has a role in engraftment of HSCs to the liver (as well
Y720, W146, or control media and injected into mice with
sed in real time by intravital microscopy. Pretreatment of
ured liver for 60 minutes after injection (P ¼ NS by 2-way
son test, n ¼ 3 per group, 6 independent experiments).
ts, liver tissue sections were analyzed by ﬂuorescent
of individual ﬂuorescent cells was counted manually in
) per section. No difference in the number of injected cells
-P, W146, or control media (n ¼ 3 each group). *P < .05.
T
Figure 7. FTY720 treatment augmented the antiﬁbrotic effect of repeated HSC injections. (A) Liver injury was induced in 8-week-old
C57/BL6mice by 8 weeks of twice-weekly intraperitoneal injections of CCl4. Mice were divided into 4 groups: injury alone, injury and
FTY720, injury and injection of 5  104 KSL cells, or injury and injection of 5  104 KSL cells and FTY720 (n ¼ 8–13 per group).
Representative photomicrograph images of PSR staining of livers show a reduction in collagen staining of livers from KSL
(± FTY720)-treatedmice, comparedwith control mice and those receiving FTY720 only (magniﬁcation, 40). (B) Quantitative analysis
of picrosirius red staining showed that FTY720 treatment with KSL cell injections reduced hepatic ﬁbrosis more than KSL injections
alone (n ¼ 8–13 per group; 5 independent experiments), with a commensurate reduction in the level of (C) hepatic hydroxyproline
(n¼ 8–13per group; 5 independent experiments). (D) Representativephotomicrograph imagesofa-SMAstaining (magniﬁcation, 40)
across the 4 groups indicated lower levels of a-SMA, as conﬁrmed by morphometric analysis (n ¼ 13 per group; 5 independent
experiments). (E) Hepatic gene expression of a-SMA and col1a1 was suppressed in both the KSL group and the KSL and FTY720
group (n ¼ 8–13 per group; 5 independent experiments). *P < .05.
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whether the number of cells administered was proportional
to the antiﬁbrotic effect or whether there is a plateau effect
beyond which no greater effect would be observed.
Our data show the potent antiﬁbrotic actions of puri-
ﬁed murine hematopoietic stem cells, and also indicate
that enhanced exposure of the target organ, the injured
liver, to infused HSCs is associated with an augmentation
of their antiﬁbrotic effect. These ﬁndings support the
development of clinical trials of stem cell therapy in
human beings.
Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2017.03.022.ReferencesBA
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Supplementary Materials and Methods
Tissue Preparation
Blood samples were obtained by cardiac puncture under
general anesthesia and mice were killed by cervical dislo-
cation. Bone marrow cells were ﬂushed from the medullary
cavities of the femur and tibia with Dulbecco’s modiﬁed
Eagle medium þ 10% fetal calf serum using a 25G needle. A
single-cell suspension was prepared by passing the cells
through a 40-um ﬁlter (BD Falcon, London, UK) and
analyzed by ﬂow cytometry or used for cell sorting. Mouse
tissues were harvested and perfused with phosphate-
buffered saline, dissociated, and digested with 2 mg/mL
collagenase IV (Sigma). Mononuclear cells were isolated by
density centrifugation using an Optiprep (Sigma) gradient
and the resulting cell suspension was used for ﬂow
cytometry. Samples of frozen human liver tissue were ob-
tained from patients at the University Hospital Birmingham
with chronic liver disease undergoing liver transplantation
or from normal organ donor liver not used for trans-
plantation with written informed consent and local ethics
committee approval.
Immunohistochemistry
Liver specimens were ﬁxed in 4% paraformaldehyde,
embedded in parafﬁn, and cut into 4-mm sections. Slides
were deparafﬁnized and antigen retrieval was performed
using a citrate buffer pH 6.0. Primary antibody was added
for 1 hour: anti–a-SMA (1:400; Abcam), anti-F4/80 (1:200;
AbD Serotec), anti-Ly6G (1:500; AbD Serotec), anti-CD45.2
(1:200; eBioscience) followed by secondary antibody
(ImmPRESSS peroxidase anti-rabbit IgG or anti-rat [mouse
adsorbed] IgG; Vector Labs), and expression was visualized
using ImmPACT DAB reagent (Vector Labs). Sections were
counterstained with hematoxylin and mounted using DPX
(Fisher Scientiﬁc).
Hydroxyproline Assay
Frozen liver tissue samples were weighed and protein
was precipitated by the addition of 1:1 trichloroacetic
acid:water and incubated on ice for 30 minutes. Samples
were hydrolyzed with 6 N HCl in sealed borosilicate tubes
and incubated at 120C for 16 hours and at 80C until
completely desiccated. The precipitate was resuspended in
water and ﬁltered. Chloramine T solution was added at
room temperature for 20 minutes, followed by the addition
of Ehrlich’s solution and incubation at 65C in a water bath
for 15 minutes. After cooling to room temperature, ﬂuo-
rescence readings at 561 nm were taken from samples and
standards, and hydroxyproline content was expressed as
mcg per gram of liver tissue.
Flow Cytometry and Cell Sorting
Erythrocytes were lysed using ACK red cell lysis buffer
(Sigma). After incubation with anti-CD16/32 antibody
(1:20; eBioscience) to eliminate nonspeciﬁc fragment crys-
tallizable receptor binding, cell suspensions were labeled
with the relevant primary antibodies (all 1:100):
anti-CD11b–ﬂuorescein isothiocyanate (M1/70), anti-CD5–
ﬂuorescein isothiocyanate (53-7.3), anti-CD8a–ﬂuorescein
isothiocyanate (53-6.7), anti-Ter119–ﬂuorescein isothiocy-
anate (TER119), anti-CD45R–ﬂuorescein isothiocyanate
(RA3-6B2), anti-Gr1–ﬂuorescein isothiocyanate (RB6-8C5),
anti-CD117 (c-kit)–PE, anti-CD117 (c-kit)-Paciﬁc Blue, anti-
CD117 (c-kit)-APC-Cy7 (all 2B8), anti-Sca1–APC (D7), anti-
CD127 (interleukin 7Ra)-PE (A7R34), anti-EDG1 (S1P1)-
PE (T4-H28), anti-CD45.1-PE (A20), anti-CD45.2-APC (104)
and incubated on ice for 30 minutes. Nonviable cells were
excluded using LIVE/DEAD stain (Invitrogen). Absolute cell
counts were determined using Trucount beads (Invitrogen)
and data were analyzed using a CyAn adenosine diphos-
phate ﬂow cytometer with Summit (London, UK) 4.3 soft-
ware. Cell sorting was performed using a MoFloCell Sorter
(Dako, London, UK) with Summit 5.2 software. Cells to be
injected were sorted directly into sterile phosphate-
buffered saline and used immediately, whereas cells for
polymerase chain reaction analysis were sorted directly
into RNeasy Lysis buffer ready for RNA extraction.
Cell Isolation From Blood and Liver and Flow
Cytometric Analysis
Blood was collected through cardiac puncture into EDTA
tubes. Red blood cells were lysed with 5 minutes of lysis
buffer. Isolated cells then were washed twice and resus-
pended in magnetic-activated cell sorting (MACS) buffer
(2% fetal calf serum and 1 mmol/L EDTA). Liver homoge-
nate was ﬁltered after being homogenized with a 5-mL sy-
ringe plunger. Single cells then were overlaid on density
gradient of Optiprep and centrifuged at 1000g for 25 mi-
nutes at room temperature. After 2 washes, isolated cells
then were suspended in MACS buffer.
Antibodies used for ﬂow cytometry are listed in
Supplementary Table 1. Single-cell suspensions were
blocked with anti-mouse fragment crystallizable region
(FcR) antibody (CD16/CD32) for 15 minutes at 4C in MACS
buffer, and stained with primary conjugated antibodies. For
internal staining, cells were ﬁxed and permeabilized with a
Foxp3/permeabilization kit (eBioscience). Flow cytometry
was performed with Fortessa (BD Biosciences) with for-
ward- and side-scatter gates set to exclude nonviable cells.
Data were analyzed with Flowjo software (version 10.1).
Flow cytometric analysis showed livermacrophages (gated
CD45þCD3-CD11bþF4/80þLy-6G-), resident (res)macro-
phages (gated CD45þCD3-CD11bintF4/80þ), M1-macrophages
(gated CD45þCD3-CD11bþF4/80þLy-6G-Ly6Chi), and
M2-macrophages (gated CD45þCD3-CD11bþF4/80þLy-6G-
Ly6-Clo).
Quantitative Reverse-Transcription Polymerase
Chain Reaction
RNA extraction was performed using the RNeasy Mini
(liver tissue) and Micro (isolated cells) kits (Qiagen) ac-
cording to the manufacturer’s instruction, concentration
and purity were checked using a Nanodrop 1000 (Thermo
Scientiﬁc). Complementary DNA was transcribed from RNA
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using iScript reverse-transcriptase (Bio-Rad). Reverse-
transcription polymerase chain reaction was performed
on an ABI Prism 7900HT or Stratagene MX3000p using
TaqMan assay mix in predesigned TaqMan assays as
detailed in the Supplementary information (Applied Bio-
systems). The program consisted of activation at 95C for
10 minutes, followed by 40 cycles of denaturing (95C for
10 seconds) and annealing (60C for 60 seconds) with
ﬂuorescence detection at the end of each cycle. Normaliza-
tion to glyceraldehyde-3-phosphate dehydrogenase using
the 2-DDCT method was performed and expression relative
to the appropriate control was calculated.
Serum Albumin
Serum albumin concentrations were determined using
the Quantichrom BCG Albumin Assay (Bioassay Systems)
according to the manufacturer’s instructions.
Western Blot
Whole-liver protein extracts were quantiﬁed using
Bradford reagent and 50 mg used for Western blot. The
primary antibody was either anti-SphK1 (1:500; Abcam) or
anti–glyceraldehyde-3-phosphate dehydrogenase (1:2000;
Sigma) incubated overnight and horseradish-peroxidase–
conjugated goat anti-rabbit IgG antibody (1:10,000; Sigma)
secondary antibody incubated for 30 minutes. Pierce
chemiluminescent peroxidase substrate and Hyperﬁlm ECL
were used to visualize protein expression.
Transwell Migration
Male C57/BL6 mice were culled by cervical dislocation
and their tibias and femurs were dissected from the
cadavers for monocyte isolation. Ends of bones were trim-
med and the bone marrow was ﬂushed out with MACS
separation (MACs) buffer (phosphate-buffered saline þ 2
mmol/L EDTA þ 0.5% bovine serum albumin). After
centrifugation and cell count, monocytes were selected from
the cell suspension using magnetic labeling and separation.
After washing, the cells were resuspended in MACs buffer
and incubated for 5 minutes at 4C with FcR Blocking Re-
agent and Monocyte Biotin-Antibody cocktail. The cells then
were washed before being incubated with Anti-Biotin
Microbeads for 10 minutes at 4C and then passed
through an LS column. The unlabeled cells represented the
monocyte population and passed through the column.
Monocytes then were incubated with cell tracker green for
20 minutes at room temperature (the cell tracker green was
diluted 1:1000 to provide a concentration of 5 mmol/L).
CCL2 was prepared in migration media (Roswell Park Me-
morial Institute þ 1% PSG þ 0.1% bovine serum albumin)
to a concentration of 100 ng/mL, and 150 mL of this added
to the receiver plate along with media alone, unstained
monocytes, and HPC-7 cells. Monocytes were washed and
resuspended in migration media to generate a density of
2  105 cells/50 mL. A total of 50 mL of stained monocytes
then were added to the Transwell insert and the plate was
incubated for 4 hours at 37C. After this incubation, samples
were collected from the receiver plate and placed into
separate ﬂuorescence-activated cell sorter tubes. Cells then
were washed, resuspended in MACs buffer, and quantiﬁed
ﬂow cytometrically.
Near-Infrared Fluorescence Imaging
DiR (Invitrogen) was dissolved in methanol (1 mg/mL)
and stored in the dark. A total of 5 mL/mL of DiR stock
solution was added to cells at 1  106/mL in complete
StemPro media (London, UK) and incubated in the dark for
30 minutes at 37 C. Cells were washed and resuspended in
100–200 mL sterile phosphate-buffered saline for re-
injection.
Near-infrared imaging was performed using the IVIS
Spectrum Imaging System (autoexposure; medium binning;
excitation wavelength, 745 nm; emission wavelength, 800
nm). Fluorescence of individual organs was determined by
Living Image Software (Perkin Elmer) using region-
of-interest analysis after subtraction of background and
expressed as radiance efﬁciency (calculated as follows:
radiance of subject/illumination intensity) to eliminate
variability in the excitation light across the ﬁeld of view.
Intravital Microscopy
C57BL6 mice with 8 weeks of CCl4 liver injury under-
went ketamine/xylazine anesthesia and carotid artery can-
nulation. Laparotomy was performed and the liver was
exteriorized and placed on the stage of an Olympus IX81
inverted microscope. One 10 power ﬁeld of view was
selected for imaging. HPC-7 cells were labeled with 5 mmol/
L CFSE and injected, 1-minute video recordings of the
selected ﬁeld of view were taken every 5 minutes until 60
minutes and analyzed for adhesion (stationary >30
seconds) of labeled cells using Slidebook software
(Intelligent Imaging Innovations, London, UK).
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Supplementary Figure 1. Bone marrow transplantation studies. (A) Recipient BoyJ (CD45.1) mice received Baytril (Bayer
Corporation, Dallas, TX) antibiotic in drinking water 1 week before and 1 week after irradiation with 9 Gy in 2 divided doses on
the same day. Bone marrow cells were obtained from donor C57BL6 (CD45.2) mice by ﬂushing of the tibia and femurs. Six
hours after irradiation donor bone marrow cells were infused into recipient mice by tail vein injection. After a 4-week recovery,
transplanted mice were divided into 2 groups at random with 1 group receiving twice-weekly intraperitoneal administration of
carbon tetrachloride (1 mg/kg) in mineral oil and the other group receiving intraperitoneal injections of mineral oil alone for a
further 8 weeks. (B and C) Samples of bone marrow and peripheral blood were treated with red cell lysis buffer and labeled with
ﬂuorescent antibodies to CD45.1 and CD45.2. Analysis of CD45 expression by ﬂow cytometry showed almost complete
CD45.2 expression after transplantation compared with CD45.1 expression before transplantation. Representative ﬂow
cytometry plots of multiple experiments are shown.
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Supplementary Figure 2. Isolation of KSL cells. Bone marrow cells were obtained from donor mice after dissection of the tibia
and femurs by ﬂushing the marrow cavity with Dulbecco’s modiﬁed Eagle medium þ 10% fetal calf serum. Cells were treated
with red cell lysis buffer and ﬁltered before labeling with ﬂuorescently conjugated antibodies to lineage speciﬁc markers
(CD11b, CD8a, CD5, Ter119, Gr-1, and B220), c-kit, and sca-1. Cells were isolated by (A) initially excluding dead cells and
debris on a forward scatter–side scatter plot and (B) excluding doublets of cells on a forward scatter–pulse width plot. (C) The
lineage-negative population was determined and (D) plotted according to the expression of c-kit and sca-1 surface markers.
HSCs were deﬁned as KSL and represented 0.05% of the total bone marrow cell population. (E) The purity of the isolated cells
then was checked by determining lineage marker, c-kit, and sca-1 expression on a sample of isolated cells.
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Supplementary Figure 3. (A – C) Flow cytometric analysis of
peripheral blood was performed to characterize the macro-
phage subsets (M1/M2) and their ratio. The following gating
strategy was used: M1-macrophages (gated
CD45þCD3-CD11bþF4/80þLy-6G-Ly6Chi) and M2-
macrophages (gated CD45þCD3-CD11bþF4/80þLy-6G-
Ly6-Clo). Data are expressed as median ± interquartile range.
PBS, phosphate-buffered saline.
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Supplementary Figure 4. S1P gene expression in extrahepatic organs. Chronic liver injury was induced in age- and
sex-matched C57/BL6 mice by twice-weekly intraperitoneal administration of carbon tetrachloride (1 mg/kg) in mineral oil for 8
weeks. Control mice received twice-weekly intraperitoneal injections of mineral oil. Mice were killed and gene expression of
sphingosine kinase 1, sphingosine kinase 2, sphingosine lyase, and sphingosine phosphatase relative to glyceraldehyde-
3-phosphate dehydrogenase was determined in (A) spleen, (B) kidney, and (C) lung. Bars represent means ± SEM fold change
relative to control mice. N ¼ 5 per group.
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Supplementary Figure 5. Hepatic gene expression across
differing etiologies of liver disease. Samples of frozen liver
tissue were obtained from either normal donor liver or
explanted livers from patients with liver disease. Gene
expression of sphingosine kinase 1, sphingosine kinase 2,
sphingosine lyase, and sphingosine phosphatase relative to
glyceraldehyde-3-phosphate dehydrogenase was deter-
mined. Bars represent means ± SEM fold change relative to
normal liver (no statistical comparison, n ¼ 3 per group). AIH,
autoimmune hepatitis; ALD, alcoholic liver disease; HCV,
hepatitis C virus; NAFLD, nonalcoholic fatty liver disease;
PBC, primary biliary cirrhosis; POD, paracetamol overdose.
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Supplementary Figure 6. FTY720 alters HSC trafﬁcking through modulation of S1P1. (A) Gene expression of S1P receptors
1–5 was determined in freshly isolated KSL cells relative to glyceraldehyde-3-phosphate dehydrogenase by the 2-DCT method.
Bars represent means ± SEM expression in 3 independent experiments. (B) Surface and total S1P1-receptor expression on
freshly isolated KSL cells was analyzed by ﬂow cytometry. Representative histograms of 3 independent experiments are
shown (grey area, isotype control; red line, S1P1 antibody). (C) A total of 1  105 KSL cells were added to the top well of a
Transwell and migration to varying concentrations of S1P was assessed over a 4-hour period. Cells migrating into the bottom
well were analyzed for expression of c-kit and sca-1 and quantiﬁed by ﬂow cytometry. KSL cells migrating to the lower well
were expressed as a percentage of the total number of KSL cells added to the top well. Bars represent the means ± SEM of 3
separate experiments. (D) S1P-receptor dependence of migration of KSL cells to S1P was assessed by placing cells in the
upper chamber of a Transwell and quantifying their migration to the presence or absence of S1P in the lower chamber.
Treatment of KSL cells with either FTY720 (S1P-receptor partial agonist) or W146 (S1P-receptor 1 antagonist) inhibited their
migration to S1P in Transwell assays (3 independent experiments). (E) Administration of daily intraperitoneal FTY720 (1 mg/kg)
for 7 days in CCl4-injured mice resulted in an increased number of KSL cells in the liver but circulating KSL cells remained
unchanged (n ¼ 6 per group; 2 independent experiments). *P < .05 and **P < .01.
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Supplementary
Figure 7. Chemokine receptor
expression on KSL and HPC-7 cells.
Gene expression of chemokine
receptors in (A) freshly isolated KSL
cells and (B) cultured HPC-7 cells
was determined by quantitative
polymerase chain reaction. Expres-
sion relative to glyceraldehyde-
3-phosphate dehydrogenase by the
2-DCT method was determined. Bars
represent means ± SEM expression
in 3 independent experiments.
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Supplementary Figure 8. Characterization of HPC-7 cell line. (A) Cultured HPC-7 cells were labeled with ﬂuorescently
conjugated antibodies to lineage markers (CD11b, CD5, CD8a, Ter119, Gr-1, and B220), c-kit, and sca-1, and analyzed by ﬂow
cytometry. Dead cells and debris were excluded by gating on a plot of forward scatter–side scatter and surface expression of
lineage markers, c-kit, and sca-1 were measured. Representative histograms are shown (isotype control, grey area; antibody,
red line). (B) HPC-7 cells were cultured in MethoCult GF media for 7 days and signiﬁcant numbers of myeloid colony-forming
cell clusters were identiﬁed. Representative image of colony forming unit granulocyte macrophage colony shown. (C) Gene
expression of S1P receptors 1–5 in cultured HPC-7 cells relative to glyceraldehyde-3-phosphate dehydrogenase by the 2-DCT
method was determined. Bars represent means ± SEM expression in 3 independent experiments. (D) Surface S1P1-receptor
expression on cultured HPC-7 cells was analyzed by ﬂow cytometry. After ﬁxation and permeabilization of the cells, total
intracellular S1P1-receptor expression also was assessed. Representative histograms of 3 independent experiments are
shown (grey area, isotype control; red line, S1P1 antibody). (E) A total of 1  106 HPC-7 cells were added to the top well of the
Transwell and migration to varying concentrations of S1P proceeded for 4 hours. Cells migrating into the bottom well were
counted using ﬂow cytometry and expressed as a percentage of the total number of HPC-7 cells added to the top well. Bars
represent the means ± SEM of 3 separate experiments.
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Supplementary Figure 9. Validation of DiR staining. (A) Fluorescence intensity of varying numbers of cells labeled with 5 mmol/L
DiR was measured using the IVIS imaging system (n ¼ 3; means ± SD ﬂuorescence shown). (B) Representative IVIS image
(ﬂuorescence intensity overlaid on photograph) of the indicated numbers of cells labeled with 5 mmol/L DiR for each. Freshly
isolated KSL cells were incubated with 5 mmol/L DiR for 10 minutes at room temperature, washed, and resuspended in media.
(C) Cell viability of labeled cells (black bars) was measured by viability dye exclusion determined by ﬂow cytometry and
compared with unlabeled cells (white bars) (n ¼ 3; means ± SD % dead cells shown). (D) Colony-forming ability in labeled
(black bars) and unlabeled (white bars) cells was measured by in vitro methylcellulose assay (n ¼ 3; means ± number of
colonies formed shown). (E) Loss of ﬂuorescence over time: 1  106 cultured HPC-7 cells were labeled with 5 mmol/L DiR for
10 minutes at room temperature, washed, and resuspended in complete media. A cell sample was taken at each time point
and mean ﬂuorescence intensity (MFI) was determined by ﬂow cytometry. (F) Potential transfer of dye from labeled to
unlabeled cells: 1  106 cultured HPC-7 cells were labeled with 5 mmol/L DiR for 10 minutes at room temperature, washed, and
resuspended in complete media together with 1  106 unlabeled HPC-7 cells. A cell sample was taken at each time point and
the percentage of ﬂuorescent DiR-labeled cells in the sample was determined by ﬂow cytometry (n ¼ 3; means ± SD %
ﬂuorescently labeled cells shown). CFU, colony-forming unit.
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Supplementary Figure 10. Use of FTY alone in model of chronic liver injury. Chronic liver injury was induced in age- and
sex-matched C57/BL6 mice by twice weekly intraperitoneal administration of carbon tetrachloride (1 mg/kg) in mineral oil for 6
weeks, mice then were allocated randomly to a treatment group. Mice in the control group continued to receive twice-weekly
injections of intraperitoneal carbon tetrachloride until week 10 and were killed 72 hours after the ﬁnal injection of carbon
tetrachloride. Mice in the FTY720 treatment group received twice-weekly carbon tetrachloride in the same way as control mice
but in addition received 3 times weekly FTY720 (1 mg/kg) via intraperitoneal injection from the start of week 7, mice were killed
at the start of week 10, 72 hours after the ﬁnal injection of carbon tetrachloride. (A) Formalin-ﬁxed parafﬁn-embedded liver
tissue sections from control mice (black bars) and mice treated with FTY720 (grey bars) were stained for picrosirius red.
Six random nonoverlapping images were obtained from each section and staining was quantiﬁed as a percentage of the image
positive for picrosirius red using ImageJ software (n ¼ 12–13 in each group; means ± SD % area stained shown; P ¼ NS).
(B) Hydroxyproline content in samples of liver tissue from control mice (black bars) and mice treated with FTY720 (grey bars)
was determined and expressed as milligrams of hydroxyproline per gram of liver tissue (n ¼ 12–13 in each group; means ± SD
hydroxyproline content shown; P ¼ NS). RNA was extracted from liver tissue of control mice (black bars) and mice treated with
FTY720 (grey bars) and using quantitative reverse-transcription polymerase chain reaction gene expression of (C) col1a1 and
(E) a-SMA were determined, normalized to glyceraldehyde-3-phosphate dehydrogenase expression, and relative to control
mice using the 2-ddCT method (n ¼ 12–13 in each group; means ± SD fold change shown; P ¼ NS). (D) Formalin-ﬁxed parafﬁn-
embedded liver tissue sections from control mice (black bars) and mice treated with FTY720 (grey bars) were stained for
a-SMA. (F) Six random nonoverlapping images were obtained from each section and staining was quantiﬁed as a percentage
of the image positive for CD45 using ImageJ software (n ¼ 12–13 in each group; means ± SD % area stained shown; P ¼ NS).
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Supplementary Table 1.Table of Antibodies Used
Antibodies Clone Conjugate Source
Live/dead APC-CY7 e780 Life Technology
CD45.2 104 eFluor 506 Ebio
Foxp3 FJK-16s APC Ebio
CD3 17A2 eFluor 450 Ebio
CD4 GK1.5 FITC Ebio
NkP46 29A1.4 PE Ebio
CD8 53-6.7 BV 786 Biolegend
LY6C HK1.4 PE Ebio
LY-6G/Gr-1 1A8-Ly6g APC Ebio
CD3 17A2 BV650 Biolegend
B220 Ra3-6B2 eFluor 450 Ebio
CD11b M1/70 PE-e610 Ebio
F4/80 BM8 PE-CY7 Ebio
CD45.2 104 FITC Ebio
CD16 93 Puriﬁed Ebio
FITC, ﬂuorescein isothiocyanate.
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